Compare LYFT Inc (LYFT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Novo Nordisk A/S — how do they compare? LYFT Inc trades at $17.37 (market cap $6.64B), while Novo Nordisk A/S trades at $45.9 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 31.3× LYFT Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| LYFT | NVO | |
|---|---|---|
Market Cap | $6.64B | $207.85B |
Sector | Industrials | Health |
52-Week High | $24.57 | $63.98 |
52-Week Low | $12.65 | $35.29 |
Enterprise Value | $6.11B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $17.26, down 1.15% today, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrates remarkable fundamental improvement with 2025 revenue reaching $6.32B and net income surging to $2.84B, achieving a 45% profit margin. Recent Q2 2026 results showed revenue growth of 16.1% with record active riders exceeding 30 million, though earnings slightly missed estimates amid higher costs.
Lyft presents a compelling turnaround story with accelerating profitability and market share gains against Uber, supported by expanding robotaxi partnerships and international growth. However, elevated valuation multiples, competitive pressures, and ongoing legal scrutiny create headwinds. With analyst consensus at $19.17 representing 11% upside potential, the stock offers growth exposure but requires monitoring of execution risks and expense management.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
